(VIANEWS) – CONTEXTVISION (CONTX.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CONTEXTVISION (CONTX.OL) | kr9.14 | 3.46% | 61.1% |
| LNA SANTE (LNA.PA) | €19.80 | 2.54% | 9.08% |
| MEDISTIM (MEDI.OL) | kr215.00 | 2.12% | 32.37% |
| VETOQUINOL (VETO.PA) | €103.00 | 1.02% | 12.13% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CONTEXTVISION (CONTX.OL)
3.46% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and Rivent 3D, an image enhancement product for 3D ultrasound. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. The company was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.47.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 19.45. Meaning, the purchaser of the share is investing kr19.45 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
Moving Average
CONTEXTVISION’s worth is above its 50-day moving average of kr8.37 and higher than its 200-day moving average of kr8.72.
Sales Growth
CONTEXTVISION’s sales growth for the current quarter is 29.8%.
More news about CONTEXTVISION.
2. LNA SANTE (LNA.PA)
2.54% Forward Dividend Yield and 9.08% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 8.68. Meaning, the purchaser of the share is investing €8.68 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.08%.
More news about LNA SANTE.
3. MEDISTIM (MEDI.OL)
2.12% Forward Dividend Yield and 32.37% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.42.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 33.49. Meaning, the purchaser of the share is investing kr33.49 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
Volume
Today’s last reported volume for MEDISTIM is 291 which is 95.83% below its average volume of 6980.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.5%, now sitting on 526.89M for the twelve trailing months.
Yearly Top and Bottom Value
MEDISTIM’s stock is valued at kr215.00 at 21:30 EST, way under its 52-week high of kr312.50 and way above its 52-week low of kr170.50.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 2.12%.
More news about MEDISTIM.
4. VETOQUINOL (VETO.PA)
1.02% Forward Dividend Yield and 12.13% Return On Equity
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Earnings Per Share
As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.97.
PE Ratio
VETOQUINOL has a trailing twelve months price to earnings ratio of 20.72. Meaning, the purchaser of the share is investing €20.72 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.13%.
Volume
Today’s last reported volume for VETOQUINOL is 1421 which is 49.14% below its average volume of 2794.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 2, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 1.02%.
More news about VETOQUINOL.
